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Abstract
Background: The specificity of hormone action arises from
complementary steric and electronic interactions between a
hormonal ligand and its cognate receptor. An analysis of such
key ligand^receptor contact sites, often delineated by mutational
mapping and X-ray crystallographic studies, can suggest ways in
which hormone^receptor specificity might be altered.
Results: We have altered the hormonal specificity of the
estrogen receptor K (ER) by making ‘coordinated’ changes in
the A-ring of the ligand estradiol and in the A-ring binding
subpocket of ER. These changes were designed to maintain a
favorable interaction when both E and ER are changed, but to
disfavor interaction when only E or ER is changed. We have
evaluated several of these altered ligand and receptor pairs in
quantitative ligand binding and reporter gene assays.
Conclusions: In best cases, the new interaction is sufficiently
favorable and orthogonal so as to represent the creation of a new
hormone specificity, which might be useful in the regulation of
transgene activity. ß 2001 Elsevier Science Ltd. All rights re-
served.
Keywords: Estrogen receptor; Hormone speci¢city; Receptor speci¢city
reengineering
1. Introduction
The speci¢city that is inherent in biological regulatory
systems can usually be traced to the speci¢c recognition of
a hormone by its cognate cellular receptor, and is thought
to arise, at least in part, from the complementary shape
and functional interactions in contact regions between the
hormone and receptor. In the nuclear hormone receptors,
a large superfamily of ligand-activated transcription fac-
tors, hormone^receptor speci¢city is illustrated by the
highly speci¢c binding and activating characteristics
shown by the receptors from di¡erent subfamilies. For
example, while estrogens and androgens activate their cog-
nate receptors at subnanomolar hormone concentrations,
cross-receptor activation typically requires 10 000^100 000
higher concentrations of the heterologous hormone. Curi-
ously, certain receptor mutations can alter hormone^re-
ceptor speci¢city. For example, compared to wild type
androgen receptor (AR), certain AR mutants have ex-
panded binding preference for androgens [1]. In the pro-
gesterone receptor (PR), a single residue is responsible for
pronounced species di¡erences in antagonist binding [2],
and a C-terminal truncation gives a mutant that binds
antagonists but not agonists [3]. Similarly, two C-terminal
mutations in the estrogen receptor (ER) have a similar
e¡ect on antagonist vs. agonist binding [4^6], and other
mutations invert the activity of estrogens and anti-estro-
gens [7]. Although these mutants were characterized some
time ago, the molecular basis for their altered speci¢city
can now be analyzed within the context of recently de-
scribed antiparallel K-helical triple sandwich structures of
the ligand binding domains (LBD) of these receptors [8].
Also, the utility of such speci¢city-shifted nuclear hor-
mone receptors in regulating the activity of transgenes
has not been overlooked (see Section 3) [9^11].
Prior to the availability of X-ray crystal structures of
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steroid receptor LBDs, we investigated in some detail the
nature of the hormone speci¢city of ER and AR by muta-
genesis. Through alanine scanning mutagenesis studies on
ER, we had concluded that the A-ring phenol of the li-
gand was positioned near portions of helices 3 and 5
[12,13]. It seemed most likely that the phenol was interact-
ing with a glutamate residue (E353) in ER, because in AR
this residue was replaced by a glutamine (Q711); this
change was well matched to the need of the cognate li-
gands for hydrogen bonding at the C(3) position (i.e., the
hydrogen bond donor of the estradiol (E) phenol was
matched with the acceptor glutamate in ER, and the hy-
drogen bond acceptor of the androgen 3-keto group was
matched with the donor glutamine in AR). We supported
this hypothesis by ¢nding that the ER E353Q mutant was
activated by estrogens with lower potency, but by andro-
gens with higher potency than wild type ER [14], a gain of
function^loss of function outcome that was expected from
a direct interaction between the E phenol and the E353
carboxylate. This interaction was subsequently demon-
strated directly by X-ray crystallography [8].
Our experience in shifting the binding speci¢city of ER
by making a de¢ned, structure-based change in both the
receptor and the ligand, suggested that this ‘reciprocal
alteration of ligand^receptor functionalities’ might be a
general paradigm for designing hormone^receptor pairs
with unique speci¢cities. In this report, we describe the
design and evaluation of a series of ER mutants and com-
plementary ligands in which we have made di¡erent recip-
rocal changes of functionality, based on demonstrated or
presumed contact sites between ligand and receptor. Con-
ceptually, our approach is related to the ‘bump^hole’ ap-
proach used by Schreiber and Shokat to alter the speci¢c-
ity small molecule^protein interactions in other systems
[15]. Some of these new receptor^ligand pairs that we
have produced have a speci¢city that is distinctly di¡erent
from that of the wild type ER and E, and they might
prove useful as transgene regulators in vivo.
2. Results
2.1. General scheme for altering hormone^receptor
speci¢city by reciprocal changes in ligand receptor
contact sites
A general scheme for achieving the desired shift in spe-
ci¢city by making reciprocal changes at the ligand^protein
interface is illustrated in Fig. 1. Starting from a particular
interaction at the E^ER interface that is an important
determinant of the speci¢city of hormone^receptor recog-
nition (ER^E box ‘MATCH’), one makes two changes:
the E molecule is altered to produce a modi¢ed ligand
(EP, left bottom), and a coordinated or reciprocal change
is made in the receptor (ERP, top right). The ultimate goal
of these changes is to achieve a new ligand^receptor spe-
ci¢city that is ‘orthogonal’ to the original one (ERP^EP
box, ‘REMATCH’). Attaining the desired orthogonality
requires, as well, that the modi¢ed ligand EP interact
poorly with the wild type ER (ER^EPbox, ‘Ligand Mis-
match’), and that the mutant receptor ERP interact poorly
with the natural ligand E (ERP^E box, ‘Receptor Mis-
match’). We have found the new terms ‘ligand mismatch’
and ‘receptor mismatch’ useful in describing the two dif-
ferent ways in which the new speci¢city needs to be su⁄-
ciently orthogonal to the original one.
Fig. 1. Scheme illustrating the interaction between ER and its ligand E. The natural match, between wild type ER and E (ER^E box) is redesigned by
altering the ligand (E to EP) and the receptor (ER to ERP) in a reciprocal fashion, so that they rematch (ERP^EP box) in an energetically favorable fash-
ion. The mismatch between altered ligand and receptor (ER^EP box) and normal ligand and mutant receptor (ERP^E box) are to be energetically unfav-
orable.
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2.2. Reciprocal exchange of substituents and functionalities
at contact sites between E and the ERK: the
C(3)^E353 contact, and contacts at adjacent sites
Initially, we sought to expand on the presumed contact
between ER E353 and C(3) position of the ligand that we
had de¢ned by our mutagenesis experiments (Fig. 2A, left)
[14] by modifying the E molecule at this site in di¡erent
ways and attempting to compensate for these modi¢ca-
tions with a reciprocal change in the ER (Fig. 2A, right).
Thus, in exchange A, we reversed the roles of ligand
hydrogen bond donor and receptor hydrogen bond accep-
tor at this site, by changing the 353 residue from an ac-
ceptor (glutamate) to a donor (serine) and the ligand cor-
respondingly from a donor (phenol) to an acceptor
(carboxylate). In exchange B, we shifted the position of
the natural interaction by one carbon atom, changing the
receptor site from a glutamate to an aspartate, and the
ligand from a phenol to a benzylic alcohol. In principle,
exchanges A and B both maintain the polar hydrogen
bonding interaction between ligand and receptor, although
in a manner that di¡ers from the glutamate^phenol inter-
action in the wild type ER^E complex. By contrast, ex-
change C is designed to replace this polar interaction with
a non-polar one, by substituting the glutamate on ER with
an alanine and the phenol on the ligand with an ether.
Once the coordinates of the ER^E complex became
available [8], we con¢rmed these initial choices by molec-
ular modeling, and we expanded the exchanges to encom-
pass positions adjacent to C-3 on the ligand, namely C(2),
C(4), and C(6), and the residues in primary contact with
these sites (Fig. 2B). We restricted our investigation to the
region near the A-ring subpocket in ERK because here the
receptor is comparatively tightly packed around the li-
gand, meaning that there are a number of close recep-
tor^ligand contacts in and near the A-ring. By contrast,
elsewhere the ¢t is loose and the receptor is rather £exible
[8,16]. Because the ER residues that make closest contact
with E positions C(2), C(4), and C(6) are all non-polar, in
each case we mutated the contact residue to an alanine
and replaced the lost bulk with a suitable non-polar sub-
stituent on E.
2.3. Activation of ER mutants with E: the receptor
mismatch
The e¡ect of mutations in ERK on receptor interaction
with E was evaluated by comparing the potency of E on
wild type ERK and ERK mutants in cotransfection assays.
These assays were performed in human breast cancer cells
(MDA-MB-231 cells), using an expression plasmid for
ERK (or various ERK mutants) and an estrogen-respon-
sive reporter plasmid containing estrogen response ele-
ments (2ERE-pS2-CAT). Dose^response curves for E
Fig. 2. Map of interactions between ERK residues and various positions in E. A: Interactions at E353 in ERK and C(3) in E. The natural interaction
(left) is to be replaced by reciprocal changes in the receptor and ligand that are designed to maintain a favorable interaction between receptor and li-
gand. B: Interactions between various residues in ERK and C(2) and C(6) of E.
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with wild type ERK and various mutant ERs are shown in
Fig. 3. In such assays, E activates reporter gene transcrip-
tion through wild type ERK with an EC50 of ca. 0.03 nM;
its potency on the mutant receptors is distinctly lower.
It is convenient to express the transcriptional potencies
of E on the ERK mutants relative to its potency on wild
type ERK. Similarly, as described below, the potency of
various modi¢ed estrogens on both wild type ERK and
ERK mutants can also be expressed relative to the potency
of E on wild type ERK. Therefore, the potency shown by
various receptors and ligands in transcription assays is
expressed as relative transcription potency (RTP) values,
RTP = [EC50(for E on wild type ERK)/EC50(for the mis-
matched or rematched ligand^receptor pairs)]U100 (see
Table 1, and later Table 3). These RTP values are directly
comparable to the relative binding a⁄nity (RBA) values
(Table 2), which are determined in competitive binding
assays, as de¢ned below.
All of the ER mutations at 353 reduced the potency of
E (Fig. 3 and Table 1). The E353S and E353A mutants
Fig. 3. ERK mutant mismatches with E. Dose^response curves for acti-
vation of transcription by E through the wild type ERK (black curve)
or three ERK mutants at amino acid 353 (E353D, E353S, and E353A)
(blue curves) were determined in a cell transfection assay in MDA-MB-
231 breast cancer cells using an estrogen-responsive responder gene
(2ERE-pS2-CAT). For a description of the color scheme, see the legend
of Fig. 4.
Table 1
Activation of ERK mutants by E (receptor mismatch)
ERK Relative transcriptional potency (RTP) of Ea
Wild type 100
E353S 0.66
E353A 0.25
E353D 22
L349A 0.42
L391A 19
L428A 14
aRTP is de¢ned as [EC50(for E on wild type ERK)/EC50(for the mis-
matched or rematched ligand^receptor pairs)]U100. On this scale, the
potency of E on wild type ER is 100.
Table 2
RBA values of E derivatives for wild type ERa
aRBA values values are determined in a competitive radiometric binding assay, using [3H]E as tracer, radioinert compound as competitor, and char-
coal-dextran to adsorb free ligand. On the RBA scale, the a⁄nity of E is set at 100%.
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show a dose^response to E that is shifted to the right by
160 and 400 fold, respectively, indicating that the very
signi¢cant functional mismatch between these residues
and the phenol of E gives an e¡ective ‘receptor mismatch’.
The E353D mutant, however, showed only a 5 fold right
shift. This mutation is the least perturbing of ER ligand
interaction and presumably requires only a minor shift in
ligand and/or residue positions to restore a productive
polar interaction between the mutant receptor and the
natural ligand E. Mutations at receptor sites close to E
positions C(2) (i.e., L349A) and C(6) (i.e., L391A and
L428) had variable e¡ects on the potency of E (Table 1).
The L349A mutation reduced the potency of E more than
200 fold, but the L428A and the L391A mutants are still
very well activated by E. Some of these RTP values are
also given in the summary Table 3.
2.4. A⁄nity of E derivatives with wild type ER: the ligand
mismatch
The degree to which a change in ligand structure a¡ects
interaction with wild type ER can be assessed in two ways,
by determining ligand binding a⁄nity with wild type ER
and by measuring potency in cell cotransfection assays
using wild type ER. The binding assays can be done
very conveniently in a competitive manner, whereby even
low a⁄nities are readily measurable. The results are given
in Table 2, as RBA values, RBA = [IC50(for E on wild type
ERK)/IC50(for the ligand on wild type ERK)]U100. These
RBA values are directly comparable to the RTP values
(de¢ned above), and some of these values are presented
in Table 3.
The degree to which a structural change at the C-3
position of E results in a ligand binding mismatch with
wild type ERK is generally understandable from the nature
of the structural and functional alteration. Simply extend-
ing the hydroxyl group by one carbon atom (from phenol
to benzylic alcohol, ligand 3) has the least e¡ect on bind-
ing a⁄nity, a feature which also compromises the e¡ec-
tiveness of exchange B (cf., Fig. 2, and see below). The C-3
carboxylate (ligand 2), which is a synthetic precursor for
ligand 3, still has signi¢cant a⁄nity for wild type ERK,
even though it has the same charge as the glutamate res-
idue at 353 with which it is presumed to be in contact. The
carboxymethyl analog (ligand 6, for exchange A, Fig. 2) is
very well mismatched with ERK, having an a⁄nity that is
Table 3
Summary of RTP of the most signi¢cant ligand^ERK combinations investigateda
Ligand no. Ligand structure RBA RTPb
wt ER E353S ER E353A ER E353D ER
1 E2 100 100 0.66 0.25 22
2 ^CO2H 3.0 3.1 2.7 ^ 9.4
3 ^CH2OH 8.3 4.4 ^ ^ 1.4
6 ^CH2CO2H 0.04 0.0056 0.078 ^ ^
7 ^OCH2CO2H 6 0.03 0.14 1.0 ^ ^
8 ^OCH2CH3 0.54 0.044 ^ 1.5 ^
9 ^OCH(CH3)2 0.3 0.025 ^ 0.25 ^
10 ^OCH2CF3 0.22 0.075 ^ 0.075 ^
11 ^CH2CH2CH3 0.16 0.01 ^ 0.52 ^
19 lactone 0.07 0.001 6 0.001 ^ ^
20 H-furan 3.0 0.005 ^ 0.003 ^
21 Me-furan 1.59 0.10 ^ 0.92 ^
22 Et-furan 0.25 0.008 ^ 0.25 ^
aRTP is de¢ned as [EC50(for E on wild type ERK)/EC50(for the mismatched or rematched ligand^receptor pairs)]U100. On this scale, the potency of E
on wild type ER is 100.
bBold numbers indicate the RTP values for E and the three best new hormone^receptor speci¢city pairs.
Fig. 4. Analysis of the transcription activation by wild type ERK with E
(black) or compound 6 (red), and by the E353S ERK mutant with E
(blue) or compound 6 (green). MDA-MB-231 cells were transfected with
the mutant or wild type ERK expression plasmids and with the 2ERE-
pS2-CAT reporter and the pCMV5b internal control plasmid, and were
treated with the indicated concentrations of E or compound 6 for 24 h.
CAT activities were normalized to L-galactosidase activity and are ex-
pressed relative to maximal wild type ERK activity with 1039 M E,
which is set at 100%. A consistent color scheme is used in Figs. 3^6:
Match ^ black; receptor mismatch ^ blue; ligand mismatch ^ red; re-
match ^ green. See Fig. 1 for a description of these terms.
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2500 fold less than E. Ligands 4 and 5, which are synthetic
precursors for ligand 6, have signi¢cantly higher a⁄nities
for ERK than does ligand 6, probably because they have
other hydrogen bonding possibilities. Both ethers (ligands
8 and 9 ; for exchange C) also have greatly reduced a⁄n-
ities for ERK, as does the propyl derivative 11. In the
furan series (20^22), the a⁄nity for ERK decreases with
the increased size of the substituent. The binding a⁄nities
of the E derivatives bearing substituents at C(2) and C(6)
(12^18), designed to be matched with the mutations shown
in Fig. 2B, are very low, except for the C(2) allyl analog
(13).
2.5. Potency of E derivatives on ER mutants: the
ligand^receptor rematch
From dose^response curves for E and the designed li-
gands with wild type ERK and the various ER mutants in
cell transfection assays, we can obtain a quantitative in-
dication of the extent to which the designed ligands are
mismatched with wild type ERK and are rematched with
the mutant ERs. Representative examples of such dose^
response curves are shown in Figs. 4^6 (note color scheme
described in the legend to Fig. 4), with the mismatches and
rematches schematized in Fig. 7. The RTP values (de¢ned
above) of the designed ligands for ERK and the various
mutants are summarized in Table 3.
2.6. Ligand rematches with E353S ERK
With the E353S ER and the carboxymethyl^E pair (ex-
change A, Fig. 2A), the mutant receptor mismatch with E
is 160 fold, as was noted from Fig. 3 and Table 1. As
shown in Fig. 4, the mismatch of ligand 6 with wild
type ERK in terms of potency in activating transcription
is extremely high, ca. 10 000 fold. This is consistent with
Fig. 5. Analysis of the transcription activation by wild type ERK with E
or compound 8, and by the E353S ERK mutant with E or compound 8.
Assays protocol and color scheme follow that described in the legend to
Fig. 4.
Fig. 6. Analysis of the transcription activation by wild type ERK with E
or compound 21, and by the E353S ERK mutant with E or compound
21. Assays protocol and color scheme follow that described in the
legend to Fig. 4.
Fig. 7. Summary of the three best new hormone^receptor speci¢city
pairs. The RTP values are summarized in an array that corresponds to
that in Fig. 1. The fold change in RTP values is shown next to each
pair of numbers.
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the very low binding a⁄nity measured for this ligand with
wild type ERK (Table 2). The rematch of ligand 6 with
E353S ERK is considerable, so that this ligand is ca. 15
fold more potent on the E353S mutant ER than on wild
type ERK. However, because the receptor mismatch of
E353S ERK with E is not very high, the potency of E
on the mutant receptor is still 5 fold greater than that of
the designed ligand.
We also investigated several other ligands, related to
ligand 6 that might have rematched with the E353S ERK
mutant (Table 3). The carboxylate ligand 2 is not e¡ective;
it is still relatively potent on wild type ERK, and it is not
well rematched with E353S ERK. The C(3)-carboxymethyl
ether, ligand 7, has the carboxyl functionality for interac-
tion with S353 and an ether oxygen to accept hydrogen
bonds from R394. It is well mismatched with ERK, and it
does rematch with the E353S ER mutant to some extent,
but not as well as does ligand 6, probably because it has
an extra atom linking the carboxyl group to the aromatic
A-ring. Lactone ligand 19 is smaller and has similar func-
tionality for accepting hydrogen bonds from E353S and
R394; again, it was very e¡ectively mismatched with wild
type ERK, but its rematch with the mutant E353S ERK
was surprisingly poor.
2.7. Ligand rematches with E353A ERK
As was noted in Fig. 3, the receptor mismatch of E with
E353A ERK is ca. 400 fold, which is better that its mis-
match with E353S ERK. The transcriptional potency mis-
match of the designed ligand 8 with wild type ERK is very
large, ca. 2000 fold (Fig. 5 and Table 3), which is even
greater than its a⁄nity mismatch. Gratifyingly, the re-
match of ligand 8 with E353A ERK is very good. As a
result, the designed ligand shows a ca. 35 fold greater
potency on this mutant ER than it does on wild type
ERK ; its potency is even 6 fold greater than that of E
on E353A ERK. Thus, as we had sought, the ligand 8^
E353A pair rematch displays a potency that is greater than
either of the two mismatched pairs, although the potency
of this reengineered hormone^receptor pair is still ca. 65
fold below that of E on wild type ERK. Our original plan
for exchange C was to match E isopropyl ether (ligand 9)
with E353A ERK ; however, the rematch of this ligand was
less good than was that of the ethyl ether 8 (Table 3).
In vivo, ethers are often rapidly dealkylated by cyto-
chrome P450-mediated metabolism. Therefore, one might
anticipate problems in extending the ligand 8^E353A ERK
pair to in vivo situations, because the dealkylation product
would be the potent ligand E. To address this issue, we
prepared an analog of this ether having three £uorine
substituents positioned L to the ether function (ligand
10), because such £uorine substitution is known to retard
metabolic dealkylation reactions of ethers [17]. Although
the tri£uoroether analog had very low a⁄nity for wild
type ERK and a very good ligand potency mismatch, it
did not show an e¡ective rematch with the E353A mutant
ER (Table 3). Molecular modeling suggests that the larger
£uorine substituents are di⁄cult to accommodate in the
constrained E353A subpocket. The large group dipole of
the tri£uoromethyl substituent might also be contributing
to these results. As another analog of ethyl ether 8, we
prepared the 3-propyl derivative 11. It is isosteric with the
ethyl ether, but lacking the ether oxygen, it loses the ca-
pacity to accept a hydrogen bond from R394. As expected,
this ligand has low a⁄nity and low potency on ERK (good
ligand mismatch), but it had only a modest (2^5 fold)
rematch (Table 3).
In a di¡erent approach to metabolically stable analogs
of ligand 8, we prepared the fused furans, ligands 20^22.
The alkyl-substituted furans 21 and 22 have low a⁄nity
for wild type ERK (i.e., good ligand mismatch), but the
unsubstituted furan 20 has substantial a⁄nity (Table 2). In
transfection assays (Fig. 6), the methyl furan (21) worked
the best ; it shows both a good ligand potency mismatch
with wild type ERK and an e¡ective rematch with E353A
ERK. The ethyl furan (22) also gave a rematch, but less
well than did 21 (not shown).
Thus, for the E353A ERK mutant, we have designed a
ligand that works very well (ligand 8) but might be meta-
bolically unstable in vivo, and another ligand (methyl fur-
an 21) that works nearly as well and is likely to be more
metabolically stable.
2.8. Other ligand rematches
As we noted in the proposed exchange B (Fig. 2A), both
the receptor mismatch of the E353D ERK mutant with E
(5 fold) and the corresponding ligand mismatch of the E
benzylic alcohol ligand 3 were relatively minimal (12 fold
in terms of binding a⁄nity and 20 fold in terms of RTP).
Thus, the opportunity for achieving a distinctive rematch
with the ligand 3-E353D ERK pair was relatively limited,
as proved to be the case (Table 3).
In the exchanges shown in Fig. 2B, we planned to re-
move non-polar residues at certain sites on ERK that were
in contact with atoms in E near C(3). According to this
strategy, we prepared the L349A, L391A, and L428A ERK
mutants. In each case, these mutants were to be paired
with the corresponding E derivatives substituted at C(2)
and C(6). While the speci¢city shift with all of these new
exchanges turned out to be less complete than with the
E353S and E353A ERK mutants discussed above, an anal-
ysis of their behavior is instructive.
Residue L349 in ERK is in close contact with the C(2)
position on E, and the L349A mutant is very e¡ectively
mismatched with E (200 fold; Table 1). Of the four C(2)
alkyl-substituted ligands we prepared, 13^16, three of
them, the 2-(3-methyl-2-butenyl) derivative (14), the 2-bu-
tyl derivative (15), and the 2-isopropyl derivative (16),
showed good ligand a⁄nity mismatch with ERK (Table
2). Surprisingly, the C(2)-allyl derivative 13 had quite
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high a⁄nity for ERK, too high for it to be useful. The
rematch for ligands 14^16 was very minimal, and the
L349A mutant was only partially activated by the modi-
¢ed compounds at high concentration (1036 M) (not
shown).
The two ERK mutants designed to interact with C(6)-
substituted estrogens, L391A and L428A, were both still
activated rather e¡ectively by E (Table 1). Because of this
rather feeble receptor mismatch, these receptors were of
little practical use in rematching studies. The two C(6)-
substituted estrogen we prepared, ligands 17 and 18, while
considerably a⁄nity and potency mismatched with wild
type ERK, were not very e¡ectively rematched (not
shown).
3. Discussion
3.1. Coordinated changes at contact sites in estrogens and
the ER can create novel hormone^receptor speci¢cities
We have developed a simple structure-based design pro-
tocol to create new hormone^receptor speci¢cities by mak-
ing coordinated changes to the ligand and to the receptor
at contact sites, changes that together maintain the ener-
getically favorable interaction between ligand and recep-
tor, but separately disrupt this interaction. We focused our
work on the subpocket of ERK that binds the A-ring of E,
because interactions here are tight and energetically im-
portant [8,16].
The three best new hormone^receptor speci¢city pairs
we have created are displayed in Fig. 7, which presents a
summary of their transcriptional potency data in an out-
line format that parallels that of Fig. 1. Molecular models
for the ¢t of these three rematched sets in the ligand bind-
ing pocket of their cognate ERK mutants, together with E
wild type ERK complex, are also shown in Fig. 8. In the
most e¡ective pair, E ethyl ether (ligand 8) with E353A
ERK, the model shows how nicely the ethyl ether is ac-
commodated by the enlarged region in the C(3) subpocket
formed by mutating the glutamate residue back to alanine.
The ¢t for the methyl furan (21) in this same pocket is also
good. These two redesigned ¢ts can be contrasted with
that of E in wild type ERK, in which the much smaller
hydroxyl group in E abuts its three hydrogen bonding
partners in ER, with no evidence of extra space.
The carboxymethyl^E ligand 6, which rematched rather
well with E353S ERK, also shows a good ¢t into the en-
larged pocket of the mutant receptor. However, despite all
of our attempts at modeling (see Section 5), we ¢nd that
Fig. 8. Models of the ligands in the binding pocket of ERK. In each case, the surface of the ligand is shown in green and the surface of the ligand
binding pocket as purple dots. A: E (1) in wild type ERK. B: Ligand 6 in E353S ERK. C: Ligand 8 in E353A ERK. D: Ligand 21 in E353A ERK.
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the carboxyl group prefers to form a strong interaction
with arginine 394, rather than serine 353. When one con-
siders the energetic importance of a salt bridge in the in-
terior of a protein and the limitations of modeling, this
¢nding is perhaps not surprising. It does suggest, however,
that there may be opportunities for further re¢nement of
this interaction by placing additional substituents on the
methylene group of this molecule to more optimally ¢ll
space that remains in the C(3) subpocket of this mutant.
In a number of other cases, coordinated changes in li-
gand^receptor pairs did not work, or worked only in part;
de¢ciencies could be because either the receptor or ligand
mismatches were insu⁄cient or the rematch was too fee-
ble. For example, mutations in ERK that did give poor
receptor mismatches, that is, not reduce E potency su⁄-
ciently, were the E353D, L391A, and L428A mutations
(Table 1). In the ¢rst case, shortening the acidic residue
at 353 by only one carbon atom did not preclude produc-
tive interaction with the phenol of E. In the last two cases
(L391A and L428A), the changes are being made at a site
on ER where the ligand binding pocket is more £exible, so
there are no polar interactions to enforce ligand^receptor
contact. The more pronounced functional group changes,
E353S and E353A, were e¡ective in reducing the binding
and potency of E, as was the L349A mutation.
The e¡ect that changes in ligand structure had on a⁄n-
ity and potency towards wild type ERK (i.e., ligand mis-
match) were, for the most part, understandable (Tables 2
and 3). The small change in ligand structure, phenol to
benzylic alcohol (ligand 3), designed to match this ligand
with E353D, had only a minor e¡ect on ligand a⁄nity and
potency on wild type ERK. However, the more profound
changes in ligand structure had greater e¡ects on ligand
a⁄nity and potency. The only unexpected ¢ndings in this
regard were the fact that carboxy E (ligand 2) still retained
signi¢cant a⁄nity and potency on wild type ERK, as did
the simple furan (ligand 20) and the 2-allyl derivative
(ligand 13). Aside from the successful ligand^receptor re-
matches noted at the start of the Discussion, there were a
number of cases where rematching was surprisingly poor.
In most of these, molecular modeling could be used, after
the fact, to show the existence of unfavorable ligand^re-
ceptor contacts.
We believe that it is signi¢cant that we found the de-
signed reengineering of reciprocal ligand^receptor contact
sites worked best within the tight steric constraints of the
A-ring binding pocket, where the polar interaction of the
phenol with its hydrogen bonding partners is dominant.
As far as we examined, designed reengineering worked less
well outside of this region, where the ligand^receptor ¢t
may be looser and the receptor more £exible [8,16]. In
these latter regions, interactions that occur more deeply
within the protein, that is, not directly at the ligand^re-
ceptor interface, are likely to be contributing to the stabi-
lization energy, so reengineering by design here may prove
to be more challenging.
3.2. Hormones and nuclear receptors with unique
speci¢cities are useful in controlling gene expression
Unique speci¢city regulatory systems are under active
investigation not only as means to control the transcrip-
tion of transgenes [10,18^20], but also to regulate enzyme
activity [6,21,22], to probe the function of certain enzymes
[21], and to regulate protein solubility [23]. There are a
number of classical approaches to the regulation of gene
expression with ligands. The metal-activated metallothio-
nein system has more recently been replaced by various
versions of the tetracycline-regulated system [24,25], and
the use of nuclear hormone receptors from di¡erent phyla,
such as using the ecdysone receptor from insects to regu-
late genes in mammalian cells, has seen wide application
[26].
There are a number of well documented cases where
nuclear receptor mutants were found that had useful shifts
in hormone speci¢city, although these were not obtained
by design (see Section 1). A potentially serious problem
encountered with most of these systems is that the ligand
being used to regulate the mutant receptor still has bio-
logical activity on endogenous receptors. Thus, in the lan-
guage of this report, the activating ligands in these systems
have not been su⁄ciently mismatched with their endoge-
nous receptors for the speci¢city of the system to be
unique.
In more recent cases, designed mutations made in the
retinoid X receptor (RXR) system led to signi¢cant
changes in hormone^nuclear receptor speci¢city, such
that the mutants were more responsive to synthetic ligands
than to the natural ligand 9-cis retinoic acid [27], but the
synthetic ligands still activated the wild type RXR. A de-
signed approach in the retinoic acid receptor system in
which charge and size changes were made, also led to
altered speci¢city, but this study did not address the e¡ect
of the natural ligand on the mutant receptors, that is, the
issue of receptor mismatch [28].
In a number of studies on ER, random mutagenesis and
phenotypic selection have been used to generate mutant
ERs that are responsive to a ligand that has very low
potency on wild type ER [29,30]. At least in these exam-
ples, one is starting with a ligand that is well mismatched
with the wild type receptor, and ER mutants that show
signi¢cantly enhanced responsiveness towards the novel
ligand have been found in this fashion. However, typically,
these mutant receptors still retain signi¢cant responsive-
ness to E, and thus are not e¡ectively mismatched with
the endogenous hormone, E.
Thus, despite some encouraging outcomes, most of
these other nuclear hormone receptor systems with modi-
¢ed speci¢city are still not optimal, because of the un-
wanted activation of the parent receptor by the small mol-
ecule drugs, or residual sensitivity of the mutant receptors
to the endogenous ligand. The new, more fully orthogonal
speci¢cities generated by redesigning molecule^protein in-
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terfaces, as illustrated in this report, may prove to be
better candidates for the development of regulated gene
expression systems.
4. Signi¢cance
Our work represents a signi¢cant step in the use of
structure-based design to achieve a pronounced shift in
hormone^receptor speci¢city in nuclear receptor systems.
A noteworthy feature of our approach is that we consider
explicitly from the beginning, not only the goal of obtain-
ing a new ligand^receptor speci¢city, both also the impor-
tance of mismatching the new ligand with the endogenous
receptor and the mutant receptor with the endogenous
hormone, E. This structure-based design approach could
also be combined, in a sequential fashion, with random
mutagenesis and phenotypic screening or selection meth-
ods (in vitro evolution), particularly when the latter would
be applied both in a positive-selection manner (with the
designed ligand) and a negative-selection manner (with the
mutant receptors counter screened against endogenous es-
trogens). In fact, this in vitro evolution approach might be
more e¡ective if one starts with a system where structure-
based design has already been used to create a system in
which the desired ligand and receptor mismatches and the
ligand^receptor rematch have been developed to a consid-
erable extent, as we have demonstrated here for ER.
Nevertheless, even with a fully optimized novel hor-
mone^receptor speci¢city set, there are obviously addition-
al challenges to be faced in using these molecular partners
to regulate gene expression in vivo.
5. Materials and methods
5.1. Chemical synthesis
A complete description of the synthesis of Ligands 2^22 is
given in the Supplementary Material, together with full experi-
mental details and compound characterization.
5.2. Biological methods
5.2.1. Binding a⁄nity determination
Determination of ligand a⁄nity for the ER was done by a
competitive radiometric binding assay using lamb uterine cytosol
as a source of receptor and tritium-labeled E as tracer, with un-
bound free ligand being removed by adsorption onto charcoal-
dextran, according to a previously described method [31]. Binding
assays were done in duplicate, and the average is listed in Tables
2 and 3 as RBA values, where the a⁄nity of E is considered to be
100%. This assay gives repeat RBA values with a coe⁄cient of
variation of 0.3.
5.2.2. Construction of ER mutants
Site-directed mutagenesis of the human ERK cDNA was per-
formed by the method of Kunkel [32], as described previously
[14]. Mutations were con¢rmed by restriction enzyme analysis,
and by sequencing using the Big Dye sequencing kit from Per-
kin-Elmer. Details are given in the Supplementary Material.
5.2.3. Transfection assays
Transfections were done in ER-negative MDA-MB-231 human
breast cancer cells and utilized the estrogen-responsive reporter
2ERE-pS2-CAT, pCMV5-wild type or mutant ERK expression
vector, and the internal control plasmid pCMVL, expressing
L-galactosidase as described [33], except that lipofectin-transferrin
transfection reagent was used instead of calcium phosphate for
DNA transfections, due to its improved e⁄ciency. Cells were
exposed to ligand for 24 h. CAT assays were performed and
were normalized to the internal L-galactosidase activity [33]. De-
tails are given in the Supplementary Material.
5.3. Supplementary material available
Experimental details regarding the synthesis of ligands 2^22,
the construction of ER mutants, and the transfection assays are
available on http://www.elsevier.com/locate/chembiol.
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